文献速递骨软组织肉瘤与黑色素瘤

基于基因表达预测肉瘤中帕唑帕尼的疗效

Gene expression-based prediction of pazopanib efficacy in sarcoma.
PubMed 文献 · Eur J Cancer · 2022-06-25

该研究分析了DKTK MASTER前瞻性观察研究中接受帕唑帕尼治疗的肉瘤患者的分子谱与临床结局。在62例有转录组数据的患者中,NTRK3、IGF1R和KDR的mRNA水平与无进展生存期独立相关,基于这三个基因表达构建的预测评分可将患者分为PFS显著不同的三组,并在独立队列(n=43)中验证。

要点

  • 在62例接受帕唑帕尼治疗且有转录组数据的肉瘤患者中,NTRK3高表达(HR=0.53,p=0.021)、IGF1R低表达(HR=1.82,p=0.027)和KDR高表达(HR=0.50,p=0.011)与无进展生存期独立相关。
  • 基于NTRK3、IGF1R和KDR表达构建的帕唑帕尼疗效预测评分将患者分为PFS显著不同的三组(p<0.0001)。
  • 在独立验证队列(n=43)中,该评分仍可区分PFS显著不同的患者组(p=0.02),而在未接受帕唑帕尼治疗的患者中未见此关联。

核心结论

  • 基于NTRK3、IGF1R和KDR联合表达的评分可识别帕唑帕尼治疗后结局良好、中等和较差的肉瘤患者,并需前瞻性研究作为预测工具以优化该药在临床中的使用。

研究设计与样本

  • 前瞻性观察研究(德国癌症联盟DKTK MASTER),采用全基因组/外显子组测序和转录组测序分析接受帕唑帕尼治疗的肉瘤患者。
  • 109例患者有全基因组/外显子组测序数据;62例在帕唑帕尼治疗前进行了分子分析且有转录组测序数据;独立验证队列43例;未接受帕唑帕尼治疗的DKTK MASTER肉瘤患者97例和癌症基因组图谱肉瘤队列256例作为对照。

主要发现

  • 在109例有全基因组/外显子组测序数据的患者中,临床参数、特定基因改变或突变特征与临床结局无相关性。
  • 在62例有转录组数据的患者中,NTRK3 mRNA水平(HR=0.53,p=0.021)、IGF1R mRNA水平(HR=1.82,p=0.027)和KDR mRNA水平(HR=0.50,p=0.011)与无进展生存期独立相关。
  • 基于NTRK3高表达、IGF1R低表达和KDR高表达的帕唑帕尼疗效预测评分将患者分为三组,PFS差异显著(p<0.0001)。
  • 在独立验证队列(n=43)中,该评分可区分PFS显著不同的患者组(p=0.02);在未接受帕唑帕尼治疗的DKTK MASTER患者(n=97)或癌症基因组图谱肉瘤队列(n=256)中未观察到这种关联。

局限性

  • 原文结论指出该预测评分需前瞻性研究作为预测工具以优化帕唑帕尼在临床中的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The multi-receptor tyrosine kinase inhibitor pazopanib is approved for the treatment of advanced soft-tissue sarcoma and has also shown activity in other sarcoma subtypes. However, its clinical efficacy is highly variable, and no reliable predictors exist to select patients who are likely to benefit from this drug. PATIENTS AND METHODS: We analysed the molecular profiles and clinical outcomes of patients with pazopanib-treated sarcoma enrolled in a prospective observational study by the German Cancer Consortium, DKTK MASTER, that employs whole-genome/exome sequencing and transcriptome sequencing to inform the care of young adults with advanced cancer across histology and patients with rare cancers. RESULTS: Among 109 patients with available whole-genome/exome sequencing data, there was no correlation between clinical parameters, specific genetic alterations or mutational signatures and clinical outcome. In contrast, the analysis of a subcohort of 62 patients who underwent molecular analysis before pazopanib treatment and had transcriptome sequencing data available showed that mRNA levels of NTRK3 (hazard ratio [HR] = 0.53, p = 0.021), IGF1R (HR = 1.82, p = 0.027) and KDR (HR = 0.50, p = 0.011) were independently associated with progression-free survival (PFS). Based on the expression of these receptor tyrosine kinase genes, i.e. the features NTRK3-high, IGF1R-low and KDR-high, we developed a pazopanib efficacy predictor that stratified patients into three groups with significantly different PFS (p < 0.0001). Application of the pazopanib efficacy predictor to an independent cohort of patients with pazopanib-treated sarcoma from DKTK MASTER (n = 43) confirmed its potential to separate patient groups with significantly different PFS (p = 0.02), whereas no such association was observed in patients with sarcoma from DKTK MASTER (n = 97) or The Cancer Genome Atlas sarcoma cohort (n = 256) who were not treated with pazopanib. CONCLUSION: A score based on the combined expression of NTRK3, IGF1R and KDR allows the identification of patients with sarcoma and with good, intermediate and poor outcome following pazopanib therapy and warrants prospective investigation as a predictive tool to optimise the use of this drug in the clinic.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Heilig CE, Laßmann A, Mughal SS, et al. Gene expression-based prediction of pazopanib efficacy in sarcoma. Eur J Cancer. 2022. PMID: 35763870. doi:10.1016/j.ejca.2022.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。